Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 5/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17179600 | 0.92 | EPHA2 (0.52) | ENPP1EPHA2KDREPHB4EGFR | |
| SCHEMBL664787 | 0.92 | EPHA2 (0.52) | ENPP1EPHA2KDREPHB4EGFR | |
| SCHEMBL3132645 | 0.89 | EPHA2 (0.55) | ENPP1EPHA2KDREPHB4EGFR | |
| SCHEMBL5437112 | 0.89 | ENPP1 (0.56) | ENPP1EPHA2KDREPHB4EGFR | |
| SCHEMBL6415927 | 0.86 | ENPP1 (0.54) | ENPP1EPHA2KDREPHB4EGFR | |
| SCHEMBL29465790 | 0.86 | PIK3CD (0.54) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL665187 | 0.86 | PIK3CD (0.54) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL29465791 | 0.86 | PIK3CD (0.54) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL2453138 | 0.86 | PIK3CD (0.54) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL1401721 | 0.85 | NSD2 (0.54) | ENPP1EPHA2KDREPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| EP-1653965-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | Astrazeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002092578-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092577-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | ENPP1 2971/4885EPHA2 2874/4885KDR 2580/4885 |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | FLT4, FLT1, VEGFA | ENPP1 2940/4885EPHA2 877/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.